Cynvenio ClearID Breast Cancer Test

Cynvenio Biosystems released its updated ClearID Breast Cancer blood test, which leverages a custom-developed NGS panel of 27 genes known to be altered in breast cancer. The updated test identifies circulating tumor cell burden and detects emerging genetic alterations that are associated with therapy resistance. The assay has been optimized to monitor patients with advanced breast cancer during the start of therapy and at regular intervals following treatment.